Exchange & Returns Information
Review Details
(0)
| Generic For | GILOTRIF |
|---|---|
| Active Ingredient | AFATINIB |
| Strength | 40MG |
| Manufacturer | BDR PHARMA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 28 TABLETS | $ 6.19 | $ 173.40 |
$ 147.39
Apply ZARVY26 (-15%)
You save $ 26.01
|
||
| 2 BOXES - 56 TABLETS | $ 6.35 | $ 355.40 |
$ 302.09
Apply ZARVY26 (-15%)
You save $ 53.31
|
||
| ★ Best Value 3 BOXES - 84 TABLETS | $ 6.59 | $ 553.20 |
$ 470.22
Apply ZARVY26 (-15%)
You save $ 82.98
|
Reference information will be available soon.
Afatin 40 is an oral anticancer medication containing afatinib 40 mg, a second-generation irreversible tyrosine kinase inhibitor (TKI) that selectively targets the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and ErbB4.
Unlike first-generation EGFR inhibitors, afatinib forms a covalent bond with its target receptors, leading to irreversible inhibition of signaling pathways that drive tumor growth and survival. This allows it to effectively block both activating EGFR mutations and certain resistance mutations, providing more durable clinical benefits.
Afatin 40 is FDA-approved for:
First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)
Second-line therapy in metastatic squamous NSCLC after platinum-based chemotherapy
Additionally, afatinib continues to be studied for its role in other solid tumors where EGFR/HER2 signaling contributes to disease progression, reinforcing its value as a broad-spectrum targeted therapy.
AntiCancer Drugs > Non-Small Cell Lung Cancer (NSCLC)
Afatinib is indicated as first-line therapy for patients with metastatic NSCLC harboring EGFR mutations such as exon 19 deletions or L858R substitutions. It inhibits downstream signaling pathways that drive tumor proliferation, survival, and metastasis. Its irreversible receptor binding ensures sustained suppression of EGFR signaling and has demonstrated benefit in patients with central nervous system (CNS) involvement.
AntiCancer Drugs > Squamous Cell Carcinoma of the Lung
Approved for metastatic squamous NSCLC in patients who have progressed after platinum-based chemotherapy. Afatinib provides a targeted therapeutic option where traditional chemotherapy may have failed, reducing tumor progression via irreversible ErbB family blockade.
AntiCancer Drugs > Head and Neck Squamous Cell Carcinoma
Under clinical investigation for recurrent or metastatic HNSCC, both as monotherapy and in combination regimens. Its activity is especially relevant in tumors with high EGFR expression, reflecting its broad inhibitory mechanism across the ErbB receptor family.
AntiCancer Drugs > Off-label EGFR-Driven Cancers
Afatinib is being studied in pancreatic, breast, and colorectal cancers where EGFR dysregulation contributes to tumor growth. These investigational uses aim to expand its role, particularly in settings of resistance to first-generation EGFR TKIs.
Afatinib works by covalently and irreversibly binding to the ATP-binding site of EGFR, HER2, and ErbB4 receptors, thereby blocking kinase activity and preventing downstream activation of the PI3K/AKT and RAS/RAF/MEK signaling pathways.
Unlike first-generation reversible TKIs, afatinib creates a long-lasting receptor blockade, minimizing the risk of receptor reactivation. This durability allows it to overcome acquired resistance commonly seen with earlier EGFR inhibitors and provides potential benefit in patients with brain metastases.
In addition, afatinib suppresses ErbB receptor heterodimerization, shutting down redundant proliferative signals across multiple pathways, which broadens its antitumor efficacy in EGFR-driven and HER2-influenced malignancies.
Adults – Non-Small Cell Lung Cancer (EGFR-mutation positive):
40 mg orally once daily
Squamous NSCLC (post-platinum chemotherapy):
40 mg orally once daily
Administration Guidelines:
→ Take on an empty stomach (≥1 hour before or ≥2 hours after meals)
→ Do not take a missed dose within 12 hours of the next scheduled dose
→ Continue therapy until disease progression or unacceptable toxicity
→ Confirm EGFR mutation status with an approved diagnostic test prior to initiation
→ Swallow tablets whole with water; do not crush or chew
Monitoring & Precautions:
→ Monitor for diarrhea, skin rash, and liver enzyme abnormalities – may require dose modifications
→ Use with caution in patients with renal or hepatic impairment
Store at room temperature below 30°C in a dry environment
Keep away from direct sunlight and moisture
Retain in original packaging to prevent degradation
Store out of reach of children
Do not expose to humidity or heat sources
Common side effects: diarrhea, acneiform rash, stomatitis, paronychia, dry skin, decreased appetite
Serious adverse events: interstitial lung disease (ILD), liver enzyme elevation, severe dehydration (from persistent diarrhea)
Cardiac toxicity: rare cases of left ventricular dysfunction have been reported
Management: if severe symptoms occur, seek prompt medical assessment; treatment interruption may be required
Dose adjustments: reductions or discontinuation may be necessary depending on tolerability and clinical response
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
